{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:18:57Z","timestamp":1791199137473,"version":"4.1.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T00:00:00Z","timestamp":1138752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T00:00:00Z","timestamp":1138752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["M\u00e9decine et Maladies Infectieuses"],"published-print":{"date-parts":[[2006,2]]},"DOI":"10.1016\/j.medmal.2005.11.012","type":"journal-article","created":{"date-parts":[[2006,2,16]],"date-time":"2006-02-16T07:21:15Z","timestamp":1140074475000},"page":"111-114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["\u00c9valuation de\u00a0l'efficacit\u00e9 et\u00a0de\u00a0la\u00a0tol\u00e9rance du\u00a0traitement antir\u00e9troviral chez\u00a0des\u00a0patients infect\u00e9s par\u00a0le\u00a0VIH-2 \u00e0\u00a0Dakar\u00a0: \u00e9tude pr\u00e9liminaire"],"prefix":"10.1016","volume":"36","author":[{"given":"C.T.","family":"Ndour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Batista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.M.","family":"Manga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.F.","family":"Ngom Gu\u00e8ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.M.","family":"Dia Badiane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Fortez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.S.","family":"Sow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medmal.2005.11.012_bib1","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1097\/00002030-199311000-00002","article-title":"Cellular and plasma viral load in patients infected with HIV-2","volume":"7","author":"Simon","year":"1993","journal-title":"AIDS"},{"key":"10.1016\/j.medmal.2005.11.012_bib2","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1126\/science.7915856","article-title":"Reduced rate of disease development after HIV-2 infection as compared to HIV-1","volume":"265","author":"Marlink","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.medmal.2005.11.012_bib3","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0014-5793(94)00793-4","article-title":"Inhibition of reverse transcriptase of human immunodeficiency virus type 1 and type 2 by two novel non-nucleoside inhibitors","volume":"330","author":"Rubinek","year":"1994","journal-title":"FEBBS Lett"},{"issue":"suppl 3","key":"10.1016\/j.medmal.2005.11.012_bib4","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1097\/00002030-200317003-00007","article-title":"Antiretroviral therapy in HIV-2 infected patients: changes in plasma viral load, CD4+ cell count, and drug resistance profiles of patients treated in Abidjan","volume":"17","author":"Adj\u00e9-Tour\u00e9","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.medmal.2005.11.012_bib5","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0149-2918(00)80044-2","article-title":"Amprenavir: a new human immunodeficiency virus type 1 protease inhibitor","volume":"22","author":"Fung","year":"2000","journal-title":"Clin. Ther."},{"key":"10.1016\/j.medmal.2005.11.012_bib6","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1097\/00002030-200207050-00008","article-title":"The senegalese government\u2019s highly active antiretroviral therapy initiative: an 18-month follow-up study","volume":"16","author":"Laurent","year":"2002","journal-title":"AIDS"},{"issue":"suppl 3","key":"10.1016\/j.medmal.2005.11.012_bib7","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1097\/00002030-200317003-00008","article-title":"Clinical, immunological and virological response to different antiretroviral regimens in a cohortnof HIV-2-infected patients","volume":"17","author":"Van Der Ende","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.medmal.2005.11.012_bib8","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1053\/jinf.2001.0792","article-title":"Antiretroviral therapy for HIV-2 infected patients","volume":"42","author":"Smith","year":"2001","journal-title":"J. Infect."},{"key":"10.1016\/j.medmal.2005.11.012_bib9","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(98)03391-1","article-title":"Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia and insulin ressistance","volume":"351","author":"Carr","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.medmal.2005.11.012_bib10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/00002030-200007070-00002","article-title":"Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection","volume":"14","author":"Mallal","year":"2000","journal-title":"AIDS"}],"container-title":["M\u00e9decine et Maladies Infectieuses"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X05003525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X05003525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T01:01:22Z","timestamp":1759971682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0399077X05003525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,2]]}},"alternative-id":["S0399077X05003525"],"URL":"https:\/\/doi.org\/10.1016\/j.medmal.2005.11.012","relation":{},"ISSN":["0399-077X"],"issn-type":[{"value":"0399-077X","type":"print"}],"subject":[],"published":{"date-parts":[[2006,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u00c9valuation de\u00a0l'efficacit\u00e9 et\u00a0de\u00a0la\u00a0tol\u00e9rance du\u00a0traitement antir\u00e9troviral chez\u00a0des\u00a0patients infect\u00e9s par\u00a0le\u00a0VIH-2 \u00e0\u00a0Dakar\u00a0: \u00e9tude pr\u00e9liminaire","name":"articletitle","label":"Article Title"},{"value":"M\u00e9decine et Maladies Infectieuses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medmal.2005.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}